AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24246498 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpal Tunnel Syndrome (CTS)
Number of subjects: 189
Study 24246498 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep apnoea
Number of subjects: 189
Study 24246498 — intervention group
Group type: EXPERIMENTAL
Intervention: Onset of symptoms
Number of subjects: 189
Study 24246498 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Neuropathy Limitation Scale
Number of subjects: 189
Study 23489975 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint oil (PO) 182 mg
Number of subjects: 13
Study 23489975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 20121647 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic prevention programme (EPP) installation
Number of subjects: 185
Study 20121647 — intervention group
Group type: COMPARATOR
Intervention: Group education session or education via e-mail, telephone, or at home
Number of subjects: 185
Study 18852339 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 1
Study 16188178 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg daily from 4 weeks before until 48 weeks after hair transplant
Number of subjects: 79
Study 16188178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 14511965 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-eclampsia and gestational hypertension
Number of subjects: 36
Study 14511965 — intervention group
Group type: COMPARATOR
Intervention: Healthy pregnant controls
Number of subjects: 36
Study 10801755 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine
Number of subjects: 54
Study 10801755 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 54
Study 8973753 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin
Number of subjects: 174
Study 8973753 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 174
Study 8973753 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Bunazosin and Atenolol
Number of subjects: 174
Study 1405352 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis in severe SLE GN
Number of subjects: 86
Study 1405352 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronicity Index (CI)
Number of subjects: 86
Study 1405352 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity Index (AI)
Number of subjects: 86
Study 1405352 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver Operator Characteristics (ROC) analysis
Number of subjects: 86
Study 3910260 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal adjustment
Number of subjects: 91
Study 3910260 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mock occlusal adjustment)
Number of subjects: 91
Study 30895506 — intervention group
Group type: EXPERIMENTAL
Intervention: Antral sparing (AS‐LSG)
Number of subjects: 50
Study 30895506 — intervention group
Group type: COMPARATOR
Intervention: Antral resection (AR‐LSG)
Number of subjects: 50
Study 30895506 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 29037769 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Pressure Threshold Loading (IPTL)
Number of subjects: 41
Study 29037769 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary Isocapnic Hyperpnea (VIH)
Number of subjects: 41
Study 29037769 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory Flow Resistive Loading (IFRL)
Number of subjects: 41
Study 26678666 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE) for 30 minutes at 40-60% intensity
Number of subjects: 19
Study 26678666 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 19
Study 26678666 — intervention group
Group type: COMPARATOR
Intervention: Control group (CT)
Number of subjects: 19
Study 26029989 — intervention group
Group type: EXPERIMENTAL
Intervention: Active device (Menopod®)
Number of subjects: 40
Study 26029989 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 40
Study 22719060 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat 0.5 mg, 1 mg, or up to 2 mg three times daily (titrated for 8 weeks, followed by 8 weeks at stable dose)
Number of subjects: 0
Study 22719060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20150526 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily
Number of subjects: 30
Study 20150526 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily + Diltiazem 60 mg 3 times daily
Number of subjects: 30
Study 18689558 — intervention group
Group type: COMPARATOR
Intervention: 0 mg lycopene/day (placebo)
Number of subjects: 77
Study 18689558 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 mg lycopene/day
Number of subjects: 77
Study 18689558 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg lycopene/day
Number of subjects: 77
Study 18689558 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lycopene/day
Number of subjects: 77
Study 15927951 — intervention group
Group type: EXPERIMENTAL
Intervention: Room air
Number of subjects: 204
Study 15927951 — intervention group
Group type: COMPARATOR
Intervention: 100 per cent oxygen
Number of subjects: 204
Study 12708762 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte depletion with aprotinin
Number of subjects: 225
Study 12708762 — intervention group
Group type: COMPARATOR
Intervention: Moderately hypothermic CPB alone (control group)
Number of subjects: 225
Study 10584290 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen specific immunotherapy with birch and/or timothy pollen allergen extract
Number of subjects: 210
Study 10584290 — intervention group
Group type: COMPARATOR
Intervention: Optimal pharmacotherapy (Control)
Number of subjects: 210
Study 8803358 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual communication skills training
Number of subjects: 87
Study 8803358 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management skills training
Number of subjects: 87
Study 8803358 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sexual communication and self-management skills
Number of subjects: 87
Study 8803358 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV education and risk sensitization
Number of subjects: 87
Study 1794369 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ornidazole
Number of subjects: 75
Study 1794369 — intervention group
Group type: COMPARATOR
Intervention: Seven-day metronidazole
Number of subjects: 75
Study 6540178 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of residual cancer tissue (RCT)
Number of subjects: 3264
Study 6540178 — intervention group
Group type: COMPARATOR
Intervention: Absence of residual cancer tissue (RCT)
Number of subjects: 3264
Study 30694697 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasotraline 4 mg/day
Number of subjects: 342
Study 30694697 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasotraline 2 mg/day
Number of subjects: 342
Study 30694697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study 30006417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive BP lowering (eGFR decline 5% to <20%)
Number of subjects: 1660
Study 30006417 — intervention group
Group type: COMPARATOR
Intervention: Usual BP (eGFR decline 5% to <20%)
Number of subjects: 1660
Study 30006417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive BP lowering (eGFR decline ≥20%)
Number of subjects: 1660
Study 30006417 — intervention group
Group type: COMPARATOR
Intervention: Usual BP (eGFR decline ≥20%)
Number of subjects: 1660
Study 26121432 — intervention group
Group type: COMPARATOR
Intervention: Cluster sets (CLU) with 70% one repetition maximum, 4 × (2 × 5) with 30 seconds between clusters and 90 seconds between sets.
Number of subjects: 24
Study 26121432 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional sets (TRD) with 70% one repetition maximum, 4 × 10 with 120-second rest.
Number of subjects: 24
Study 25270214 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinfeng capsule (XFC), 3 tablets each time, tid, n=70
Number of subjects: 140
Study 25270214 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylazosulfapyridine (SASP), 4 pills each time, bid, n=70
Number of subjects: 140
Study 25270214 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group, n=60
Number of subjects: 140
Study 20518806 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg QD for 12 weeks
Number of subjects: 209
Study 20518806 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 20 mg QD for 12 weeks
Number of subjects: 209
Study 20518806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 16140092 — intervention group
Group type: EXPERIMENTAL
Intervention: Alarm monotherapy
Number of subjects: 105
Study 16140092 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin combined with alarm
Number of subjects: 105
Study 16140092 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine combined with alarm
Number of subjects: 105
Study 12387554 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent Transitions Program (ATP) intervention
Number of subjects: 672
Study 12387554 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 672
Study 9432341 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC400 + CLAR (Ranitidine bismuth citrate 400 mg bid with clarithromycin 250 mg qid for 14 days)
Number of subjects: 95
Study 9432341 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC800 + CLAR (Ranitidine bismuth citrate 800 mg bid with clarithromycin 250 mg qid for 14 days)
Number of subjects: 95
Study 9432341 — intervention group
Group type: COMPARATOR
Intervention: RBC400 (Ranitidine bismuth citrate 400 mg bid alone for 4 weeks)
Number of subjects: 95
Study 7523450 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 mg DEP nasal challenge
Number of subjects: 0
Study 2452997 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (alpha-adrenergic agonist)
Number of subjects: 7
Study 11737617 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron management based on serum ferritin and transferrin saturation
Number of subjects: 157
Study 11737617 — intervention group
Group type: COMPARATOR
Intervention: Iron management based on CHr
Number of subjects: 157
Study 30830474 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA 400 mg daily for 2 weeks
Number of subjects: 0
Study 30830474 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA 800 mg daily for 2 weeks
Number of subjects: 0
Study 30830474 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA 1200 mg daily for 2 weeks
Number of subjects: 0
Study 30474426 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher circulating endostatin levels
Number of subjects: 1536
Study 30474426 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-, sex-, and cohort-matched)
Number of subjects: 1536
Study 26749073 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (EPA + DHA; 8-10 g over 2-5 days preoperatively, then 2 g/day postoperatively)
Number of subjects: 479
Study 26749073 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 479
Study 24784512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-laminated (LM) mouthguards
Number of subjects: 412
Study 24784512 — intervention group
Group type: COMPARATOR
Intervention: Over-the-counter (OTC) mouthguards
Number of subjects: 412
Study 23167481 — intervention group
Group type: EXPERIMENTAL
Intervention: Pit and fissure sealants (PFS) applied at baseline and re-examined at 6, 12, 18, 24, and 30 months
Number of subjects: 920
Study 23167481 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish (FV) applied at baseline, 6, 12, 18, 24, and 30 months
Number of subjects: 920
Study 19585071 — intervention group
Group type: COMPARATOR
Intervention: Blind basket procedure (group A)
Number of subjects: 63
Study 19585071 — intervention group
Group type: EXPERIMENTAL
Intervention: Choledochoscopy‐assisted procedure (group B)
Number of subjects: 63
Study 17392540 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (1-8 mg once daily)
Number of subjects: 285
Study 17392540 — intervention group
Group type: COMPARATOR
Intervention: Metformin (500-1000 mg twice daily)
Number of subjects: 285
Study 17392540 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 285
Study 17392540 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 285
Study 15356074 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I/IGFBP‐3 (0.1 mg/kg.d)
Number of subjects: 15
Study 15356074 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I/IGFBP‐3 (0.4 mg/kg.d)
Number of subjects: 15
Study 15356074 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I/IGFBP‐3 (0.8 mg/kg.d)
Number of subjects: 15
Study 15356074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 11591843 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed IV methylprednisolone (IVMP) - 1 g/day for 5 days every 4 months for 3 years, then every 6 months for 2 years
Number of subjects: 88
Study 11591843 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed IV methylprednisolone (IVMP)
Number of subjects: 88
Study 11591843 — intervention group
Group type: COMPARATOR
Intervention: Control group (IVMP only for relapses)
Number of subjects: 88
Study 9727767 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function tests and surgical interventions (aortopexy, tissue expander implantation, laser ablation)
Number of subjects: 2
Study 9727767 — intervention group
Group type: COMPARATOR
Intervention: Control group of nine term healthy neonates
Number of subjects: 2
Study 8059023 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEpo) treatment
Number of subjects: 0
Study 8059023 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 0
Study 8059023 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hemodialysis and rHuEpo
Number of subjects: 0
Study 8059023 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 2647294 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha 2b-interferon with indomethacin
Number of subjects: 53
Study 2647294 — intervention group
Group type: COMPARATOR
Intervention: alpha 2b-interferon without indomethacin
Number of subjects: 53
Study 29761211 — intervention group
Group type: EXPERIMENTAL
Intervention: UMA Jeunesse Ultra® (UJU)
Number of subjects: 75
Study 29761211 — intervention group
Group type: COMPARATOR
Intervention: UMA Jeunesse Classic® (UJ)
Number of subjects: 75
Study 28780563 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modal support service programme including mail-delivered cognitive behavioural therapy, telephone-delivered group counselling, and education on community services/resources.
Number of subjects: 360
Study 28780563 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modal support service programme.
Number of subjects: 360
Study 28780563 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group.
Number of subjects: 360
Study 26505201 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga program (60-minute session twice a week for 8 weeks)
Number of subjects: 52
Study 26505201 — intervention group
Group type: COMPARATOR
Intervention: Control group (no yoga practice, maintain usual physical activity)
Number of subjects: 52
Study 26505201 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga program
Number of subjects: 52
Study 26505201 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 24565712 — intervention group
Group type: EXPERIMENTAL
Intervention: FENO-guided treatment
Number of subjects: 187
Study 24565712 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 187
Study 21546164 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (40 IU intranasal)
Number of subjects: 27
Study 21546164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 21546164 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 27
Study 18463442 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin (6 microg/kg) during placebo treatment
Number of subjects: 19
Study 18463442 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (40 mg bid) treatment
Number of subjects: 19
Study 18463442 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole treatment
Number of subjects: 19
Study 16271414 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic strains Lactobacillus gasseri CECT5714 and Lactobacillus coryniformis CECT5711
Number of subjects: 30
Study 16271414 — intervention group
Group type: COMPARATOR
Intervention: Standard yogurt (control)
Number of subjects: 30
Study 15345738 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (800 mg/day) combined with testosterone injections (100 mg/week)
Number of subjects: 0
Study 15345738 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (800 mg/day) combined with placebo injections
Number of subjects: 0
Study 15345738 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (800 mg/day) combined with resistance training
Number of subjects: 0
Study 15345738 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (800 mg/day) combined with resistance training and testosterone
Number of subjects: 0
Study 15345738 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo injections)
Number of subjects: 0
Study 10646150 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracapsular cataract extraction (ECCE)
Number of subjects: 55
Study 10646150 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 55
Study 9071805 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental stimuli (combinations of corn syrup and water with viscosities ranging from 2 to 2,240 cP)
Number of subjects: 20
Study 9071805 — intervention group
Group type: COMPARATOR
Intervention: Anchor stimuli representing the extremes of the range of viscosities
Number of subjects: 20
Study 8365017 — intervention group
Group type: EXPERIMENTAL
Intervention: Early OME diagnosed by tympanometric screens and assessed by language tests at pre-school age.
Number of subjects: 47
Study 8365017 — intervention group
Group type: EXPERIMENTAL
Intervention: Language, reading, and spelling tests conducted at school age.
Number of subjects: 47
Study 2429334 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg tiropramide per day
Number of subjects: 40
Study 2429334 — intervention group
Group type: COMPARATOR
Intervention: 1200 mg imecromone per day
Number of subjects: 40
Study 31340206 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant Chemoradiation Therapy (NACRT)
Number of subjects: 5371
Study 31340206 — intervention group
Group type: COMPARATOR
Intervention: Neo-adjuvant Chemotherapy (NAC)
Number of subjects: 5371
Study 31340206 — intervention group
Group type: EXPERIMENTAL
Intervention: NACRT
Number of subjects: 5371
Study 31340206 — intervention group
Group type: COMPARATOR
Intervention: NAC
Number of subjects: 5371
Study 29784257 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient empowerment (provision of detailed information booklet and patient diary)
Number of subjects: 91
Study 29784257 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 91
Study 29784257 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient empowerment
Number of subjects: 91
Study 27678438 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa oil (3 g/day) with a low-calorie diet
Number of subjects: 90
Study 27678438 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 g/day) with a low-calorie diet
Number of subjects: 90
Study 24891946 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge eating behavior reported at baseline, 12 months, and 24 months.
Number of subjects: 419
Study 24891946 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge eating behavior across the study period (presence or absence at each time point).
Number of subjects: 419
Study 24891946 — intervention group
Group type: COMPARATOR
Intervention: Weight regain rates between those who reported binge eating and those who did not.
Number of subjects: 419
Study 21937526 — intervention group
Group type: EXPERIMENTAL
Intervention: Posture corrective exercise programme in addition to ultrasound and infrared radiation
Number of subjects: 96
Study 21937526 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound and infrared radiation
Number of subjects: 96
Study 20235203 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicella vaccine (VV)
Number of subjects: 25
Study 20235203 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children and adolescents)
Number of subjects: 25
Study 18514633 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids (AAs) supplementation, 70.6 kcal/day (8 g of AA snacks) given at 10.00 am and 5.00 pm
Number of subjects: 34
Study 18514633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 15885167 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb administration before operation and at 1 day and 2 days after operation
Number of subjects: 31
Study 15885167 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb administration
Number of subjects: 31
Study 15885167 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rhubarb administration)
Number of subjects: 31
Study 15885167 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received an isocaloric and isonitrogenous enteral diet
Number of subjects: 31
Study 11952024 — intervention group
Group type: EXPERIMENTAL
Intervention: Emedastine difumarate 0.05% ophthalmic solution
Number of subjects: 45
Study 11952024 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate 0.025% ophthalmic solution
Number of subjects: 45
Study 11952024 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 45
Study 9925236 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-dihydroergocryptine
Number of subjects: 68
Study 9925236 — intervention group
Group type: COMPARATOR
Intervention: lisuride
Number of subjects: 68
Study 7473999 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive hypercapnia (PH)
Number of subjects: 39
Study 7473999 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 39